The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone.

摘要: Recent advances in clinical, pathological and neuroscience studies have identified disease-modifying therapeutic approaches for Alzheimer's disease that are now clinical trials. This has highlighted the need reliable convenient biomarkers both early diagnosis a rapid signal of drug efficacy. We describe identification assessment number candidate patients with correlation those rosiglitazone efficacy, as represented by change Disease Assessment Scale-Cognitive (ADAS-Cog). Plasma from 41 were analysed open platform proteomics at baseline after receiving 8 mg 24 weeks. From comparison protein expression following treatment rosiglitazone, 97 proteins observed to be differentially expressed p-value<0.01. this analysis recently published data our laboratory, prioritized list 10 immunoassay and/or functional assay wider set samples same study, representing dose response, order verify changes observed. A these appeared show ADAS-Cog higher doses compared placebo. Alpha-2-macroglobulin, complement C1 inhibitor, factor H apolipoprotein E showed score (4 mg). These results discussed light pathology other data.